Literature DB >> 29955541

Outcomes comparison of long-acting injectable antipsychotic initiation in treatment-naïve veterans in the inpatient versus outpatient setting.

Nicole Romstadt1, Erica Wonson2.   

Abstract

INTRODUCTION: Long-acting injectable (LAI) antipsychotics have become an integral component in the treatment of schizophrenia and other psychotic disorders. Long-acting injectables may be initiated in either the inpatient or outpatient setting; however, there have been no studies to evaluate whether LAI treatment initiation setting impacts patient outcomes. This study sought to assess whether outcomes, specifically psychiatric hospitalization rates, time to hospitalization, and adherence with injections, differed between patients started on LAIs in the inpatient versus outpatient setting.
METHODS: The electronic medical records of all veterans prescribed an LAI at the McGuire Veterans Affairs Medical Center from September 2009 through September 2014 were reviewed in this retrospective study. Veterans met inclusion criteria if they were prescribed an LAI during the study period and were excluded if they had received an LAI prior to September 2009 or if the LAI was started at an outside facility. Patients were separated into treatment groups according to initiation location. The primary outcomes included psychiatric hospitalization rates and time to hospitalization. The secondary outcome measured the proportion of LAI injections received.
RESULTS: Fifty-five LAI treatment-naïve veterans were included in this study. No statistically significant differences were found in psychiatric hospitalization rates, time to hospitalization, or proportion of LAI injections received when comparing the inpatient and outpatient treatment initiation groups. DISCUSSION: Psychiatric hospitalization rates, time to hospitalization, and adherence to LAIs did not differ between the inpatient and outpatient treatment groups, suggesting that treatment initiation location does not have an effect on patient outcomes.

Entities:  

Keywords:  antipsychotics; long-acting injectable antipsychotics; psychotic disorders; schizophrenia

Year:  2018        PMID: 29955541      PMCID: PMC6007523          DOI: 10.9740/mhc.2018.01.024

Source DB:  PubMed          Journal:  Ment Health Clin        ISSN: 2168-9709


  8 in total

Review 1.  Practice guideline for the treatment of patients with schizophrenia, second edition.

Authors:  Anthony F Lehman; Jeffrey A Lieberman; Lisa B Dixon; Thomas H McGlashan; Alexander L Miller; Diana O Perkins; Julie Kreyenbuhl
Journal:  Am J Psychiatry       Date:  2004-02       Impact factor: 18.112

Review 2.  The case for long-acting antipsychotic agents in the post-CATIE era.

Authors:  H A Nasrallah
Journal:  Acta Psychiatr Scand       Date:  2007-04       Impact factor: 6.392

Review 3.  Interventions to improve adherence to antipsychotic medication in patients with schizophrenia--a review of the past decade.

Authors:  E Barkhof; C J Meijer; L M J de Sonneville; D H Linszen; L de Haan
Journal:  Eur Psychiatry       Date:  2011-05-10       Impact factor: 5.361

Review 4.  Prevalence of and risk factors for medication nonadherence in patients with schizophrenia: a comprehensive review of recent literature.

Authors:  Jonathan P Lacro; Laura B Dunn; Christian R Dolder; Susan G Leckband; Dilip V Jeste
Journal:  J Clin Psychiatry       Date:  2002-10       Impact factor: 4.384

5.  Antipsychotic adherence over time among patients receiving treatment for schizophrenia: a retrospective review.

Authors:  Marcia Valenstein; Dara Ganoczy; John F McCarthy; Hyungjin Myra Kim; Todd A Lee; Frederic C Blow
Journal:  J Clin Psychiatry       Date:  2006-10       Impact factor: 4.384

Review 6.  Medication adherence in patients with schizophrenia.

Authors:  Stephanie V Phan
Journal:  Int J Psychiatry Med       Date:  2016       Impact factor: 1.210

7.  Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness.

Authors:  Pierre Michel Llorca; Mocrane Abbar; Philippe Courtet; Sebastien Guillaume; Sylvie Lancrenon; Ludovic Samalin
Journal:  BMC Psychiatry       Date:  2013-12-20       Impact factor: 3.630

Review 8.  Nonadherence with antipsychotic medication in schizophrenia: challenges and management strategies.

Authors:  Peter M Haddad; Cecilia Brain; Jan Scott
Journal:  Patient Relat Outcome Meas       Date:  2014-06-23
  8 in total
  1 in total

1.  Assessing Outcomes Between Risperidone Microspheres and Paliperidone Palmitate Long-Acting Injectable Antipsychotics Among Veterans.

Authors:  Hajer G Ibrahim; Benjamin J Malcolm; Hyma P Gogineni
Journal:  Fed Pract       Date:  2021-12-12
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.